Anzeige
Mehr »
Login
Donnerstag, 21.11.2024 Börsentäglich über 12.000 News von 677 internationalen Medien
Von Solarenergie zu digitalen Assets: Die Strategie hinter der 75-Prozent-Rallye
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PHHE | ISIN: US65343E1082 | Ticker-Symbol: 2US
Tradegate
19.11.24
16:48 Uhr
1,230 Euro
-0,038
-3,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NEXTCURE INC Chart 1 Jahr
5-Tage-Chart
NEXTCURE INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,2041,27018:27
1,1981,26618:26

Aktuelle News zur NEXTCURE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiNextCure: Preclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis Imperfecta2
08.11.NextCure, Inc. - 8-K, Current Report-
08.11.NextCure goes all in on B7-H4, stopping other programs to challenge Big Pharma in ADC space2
08.11.NextCure GAAP EPS of -$0.411
08.11.NextCure Inc reports results for the quarter ended in September 30 - Earnings Summary1
NEXTCURE Aktie jetzt für 0€ handeln
07.11.NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results239Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-endCash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md....
► Artikel lesen
07.11.NextCure, Inc. - 10-Q, Quarterly Report-
05.11.NextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual Meeting4
04.10.NextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual Meeting2
16.09.NextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 20242
02.08.NextCure GAAP EPS of -$0.55 misses by $0.172
01.08.NextCure, Inc. - 10-Q, Quarterly Report-
20.06.NextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference2
18.06.NextCure, Inc. - 8-K, Current Report3
30.05.NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 20243
08.04.NextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024115BELTSVILLE, Md., April 08, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class...
► Artikel lesen
21.03.NextCure Provides Business Update and Reports Full Year 2023 Financial Results327Prioritizing and focusing on highest-value opportunities NC410 (ovarian and CRC) and LNCB74 (B7-H4 ADC)Based on early evidence of clinical activity with NC410 combo, expanding ovarian and CRC cohorts...
► Artikel lesen
05.03.NextCure Publishes Preclinical Data Demonstrating Function of FLRT3 as a T Cell Inhibitor in Science Advances192BELTSVILLE, Md., March 05, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...
► Artikel lesen
18.01.NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders324BELTSVILLE, Md., Jan. 18, 2024 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines...
► Artikel lesen
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1